Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of an offer to purchase for cash (the “Cash Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal amount, on the terms and conditions set forth in the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the “Cash Offer Documents”). No consents to any amendment or waiver of the terms of the indenture governing the Notes are being solicited in connection with the Cash Offer.

Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only

CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the commencement of a private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling $1.75 billion in aggregate principal amount, for a new series of senior notes to be issued by Biogen (the “New Notes”) and cash, if any, on the terms and conditions set forth in the Offering Memorandum dated February 4, 2021 (the “Offering Memorandum”) and the accompanying eligibility letter (the “Eligibility Letter”), Canadian beneficial holder form and notice of guaranteed delivery (collectively, the “Exchange Offer Documents”). No consents to any amendment or waiver of the terms of the indenture governing the Old Notes are being solicited in connection with the Exchange Offer.

Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors

Biogen Inc. (NASDAQ: BIIB) said on Wednesday that its profit in the fiscal fourth quarter came in weaker than expected. Its revenue, however, topped analysts' estimates in Q4.

Biogen Inc misses estimates for profit in the fiscal fourth quarter

Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales.

Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates

Biogen Inc. (BIIB) CEO Michel Vounatsos on Q4 2020 Results - Earnings Call Transcript

The biotech's 2021 guidance was the worst news of all with its Q4 update.

Why Biogen's Q4 Results Were a Bust

Biogen stock tripped Wednesday on disappointing 2021 guidance that accounts for "a sharp decline" in sales of MS drug Tecfidera and "significant erosion" for cancer drug Rituxan. The post Biogen Crumbles; Disappointing 2021 Outlook Calls For A 'Sharp Decline' appeared first on Investor's Business Daily.

Biogen Crumbles; Disappointing 2021 Outlook Calls For A 'Sharp Decline'

Biogen CEO Michel Vounatsos sees a “reset year” financially for the biotech. Wall Street was wary, but one analyst sees the pullback as an opportunity.

Biogen Stock Is Falling Because Earnings Guidance Came Up Short

Biogen Inc. (BIIB) delivered earnings and revenue surprises of -7.10% and 1.22%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Misses Q4 Earnings Estimates

On Wednesday, February 03, Biogen (NASDAQ:BIIB) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Preview: Biogen's Earnings

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports fourth-quarter earnings.

Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?

CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved a new intramuscular (IM) injection route of administration for PLEGRIDY® (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis (MS). The new IM administration offers people living with relapsing MS the well-characterized efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. This approval expands Biogen's industry-leading portfolio of MS treatments, which also includes the subcutaneous (SC) administration of PLEGRIDY, and follows the European Commission's marketing authorization for the IM administration in December 2020.

Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis

Amgen

Gilead Sciences

Merck

Pfizer

AbbVie

Alexion Pharma

Bristol-Myers

Regeneron Pharmaceuticals

Earnings season is in full swing, and we have put together a preview of some of the world's largest players in the health care sector reporting this coming week.

Amgen, Biogen, Gilead, Merck, Pfizer, and More Health Care Earnings Coming This Week

In early December, Court of Appeals heard oral argument regarding Biogen's only unexpired patent on Tecfidera, which was found invalid by a West Virginia judge. Biogen's CEO said at the JP Morgan Conference a couple weeks ago that the company will face abrupt erosion of Tecfidera in 2021.

Will Biogen Get Tecfidera Patent Reinstated By Appeals Court?

Biotechnology stocks and sector-related exchange traded funds stood out Friday after regulators breathed new life into Biogen (NasdaqGS: BIIB) and its partner Eisai Co. (ESALY) on a new Alzheimer's drug candidate. Among the top performing non-leveraged ETFs of Friday, the VanEck Vectors Biotech ETF (BBH) rose 2.1% and iShares Nasdaq Biotechnology ETF (IBB) gained 0.6%.

Biotechnology ETFs Soar on Biogen's New Alzheimer's Drug

The Food and Drug Administration is delaying its decision deadline for Biogen and Eisai's hotly debated Alzheimer's disease drug, a move that analysts said bodes well for Biogen.  Cambridge, Massachusetts-based Biogen said Friday that the FDA's decision on its drug aducanumab has been pushed back by three months, moving the deadline from March 7 to June 7.

The FDA is delaying a controversial Alzheimer's drug decision. Analysts say that's a good sign.

3D Systems

Duke Energy

Ford Motor Company

Akebia Therapeutics

Harley-Davidson

Lexicon Pharmaceuticals

Vail Resorts

PulteGroup

Sorrento Therapeutics Inc

With the trading day practically over, the broad markets were sliding into the weekend.

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon's Analyst Calls

The company's potential drug for Alzheimer's disease continues to generate headlines.

Why Biogen Stock Popped Today

Biogen Inc. shares rose 9% Friday, after the company said the U.S. Food and Drug Administration has extended the review period for its investigational Alzheimer's disease treatment aducanumab by three months. As part of the review, Biogen submitted a response to an information request from the regulator and provided it with additional data and analyses, "which the FDA considered a Major Amendment to the application that will require additional time for review," Biogen said in a statement.

Biogen shares jump 9% after FDA extends review period for Alzheimer's treatment

Biopharmaceutical concern Biogen Inc (NASDAQ:BIIB) is up 7.9% to trade at $291.00 this morning, after the Food and Drug Administration (FDA) extended the review period for Biogen's experimental Alzheimer's disease treatment aducanumab.

Options Traders Pile on Biogen Stock Following FDA Update

Biogen stock popped Friday after the Food and Drug Administration extended the review period for its key Alzheimer's treatment by three months. The post Biogen Stock Pops After FDA Extends Review For Key Alzheimer's Drug appeared first on Investor's Business Daily.

Biogen Stock Pops After FDA Extends Review For Key Alzheimer's Drug

Biogen Inc (NASDAQ: BIIB) shares are up sharply Friday after the company announced a delay in the FDA decision for its Alzheimer's treatment candidate, aducanumab. What Happened: The FDA has extended the review period for the biologic license application for aducanumab by three months, Biogen and Eisai Co., Ltd (OTC: ESALY) said in a statement.

Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months

The stock price of Biogen Inc (NASDAQ: BIIB) is trading at over 10% pre-market today. This is why it happened.

BIIB Stock Price Increases Over 10% Pre-Market: Why It Happened

Biogen Inc and partner Eisai Co Ltd said on Friday the U.S. Food and Drug Administration has extended the review period for their experimental Alzheimer's disease treatment by three months.

U.S. FDA extends review period for Biogen's Alzheimer's drug

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021

News for Biogen Stock (BIIB)